Antibodies
23 December 2022
UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab23 December 2022
Merck KGaA, Darmstadt, Germany Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates23 December 2022
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma23 December 2022
Elpiscience Announces CDE IND Clearance of ES014, a First in Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors22 December 2022
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia22 December 2022
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults22 December 2022
Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease21 December 2022
Innovative Antibody Discovered by RQ Bio Enters Clinic as Part of Antibody Combination Within 12 Months of Discovery21 December 2022
Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma21 December 2022
Imfinzi plus chemotherapy approved in the EU as first immunotherapy regimen for patients with advanced biliary tract cancer20 December 2022
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab19 December 2022
Update on PEARL Phase III trial of Imfinzi monotherapy in Stage IV non-small cell lung cancer19 December 2022
Enhertu approved in the EU for patients with previously treated HER2-positive advanced gastric cancer17 December 2022
TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibodyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports